Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction. The aim of this study was to evaluate the perspectives of psoriasis patients on biosimilar medications. Materials and Methods: We conduct...
Main Authors: | Alexandra Azevedo, Andreia Bettencourt, Manuela Selores, Tiago Torres |
---|---|
Format: | Article |
Language: | English |
Published: |
Ordem dos Médicos
2018-09-01
|
Series: | Acta Médica Portuguesa |
Subjects: | |
Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10127 |
Similar Items
-
Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary
by: Arnon D. Cohen, MD, MPH, PhD, et al.
Published: (2020-12-01) -
An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01) -
Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis
by: Inês Raposo, et al.
Published: (2019-03-01) -
Biosimilar bidding in centralized tenders in Norway
by: Dag Morten Dalen, et al.
Published: (2021-01-01) -
Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)